Jc. Lundell et al., REDUCTION OF POSTBURN HYPERALGESIA AFTER LOCAL INJECTION OF KETOROLACIN HEALTHY-VOLUNTEERS, Anesthesiology, 84(3), 1996, pp. 502-509
Background: Nonsteroidal antiiflammatory drugs may be particularly eff
ective against prostaglandin-mediated, postinjury hyperalgesia and rel
ated inflammatory pain. However, their usefulness may be limited by th
eir systemic side effects. The current study determined if local effec
tiveness can be achieved by low-dose intradermal nonsteroidal antiifla
mmatory drug administration. Methods: Ten healthy volunteers were aske
d to make magnitude estimations of the pain induced by a contact therm
al stimulator at 1 degrees C increments between 43 and 51 degrees C at
three 1 X 1 cm study sites on each forearm during three study phases:
(1) baseline; (2) after pretreatment with 10 mu l 0.9% saline (n = 1
site on each forearm), 0.3 mg ketorolac (n = 1 on each forearm), or no
thing (n = 1 on each forearm); and (3) after ''injury'' by a mild burn
at the ketorolac- and saline-treated sites on one arm or by injection
of 10 nmol bradykinin at all three sites on the other arm. The effect
s of pretreatment on the pain induced by thermal testing were assessed
using repeated-measures analysis of variance. Results Pretreatment wi
th ketorolac had a selective effect on the postburn injury hyperalgesi
a, reducing the increase In pain intensity (P < 0.05) but not the decl
ine in pain threshold. It had no effect on the responses to thermal st
imuli before injury or on the pain of burning, which were similar at k
etorolac- and saline-treated sites. The effect of pretreatment with ke
torolac on bradykinin-induced hyperalgesia could not be tested because
hyperalgesia was not achieved after bradykinin infection at sites pre
treated with saline as well as ketorolac. Conclusions: The findings in
dicated that local infection of ketorolac can provide local analgesia.
The selective nature of the ketorolac-induced analgesia may account f
or the partial effectiveness of nonsteroidal antiinflammatory drugs in
clinical settings.